MPMarkos Poulopoulos

Markos Poulopoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Markos Poulopoulos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Arthur G. Kane

    Department of Radiology, Neuroradiology, Eastern Maine Medical Center, 489 State St, Bangor, ME 04401, USA

    1 shared publication
  • Carol Moskowitz

    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, USA

    1 shared publication
  • Cheryl Waters

    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, USA

    1 shared publication
  • David Silvers

    From the Department of Neurology, Hartford Hospital and University of Connecticut School of Medicine

    1 shared publication
  • Etty Cortes

    Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, USA

    1 shared publication
  • Jacques M. Reynolds

    Department of Internal Medicine, UMass Memorial Medical Center 55 N Lake Ave Worcester, MA 01605

    1 shared publication

Latest Publications

  • Open Access

    Post-traumatic tics and tetrabenazine treatment: a blinded video assessment

    by Markos Poulopoulos, Mirna Hajjar

    Traumatic head injury is a very rare cause of secondary tic disorders. We add another case by describing, for the first time, the response to tetrabenazine in a blinded video assessment. Our patient had a severe traumatic head injury and subsequently developed tics refractory to various agents including neuroleptics. We assessed tetrabenazine treatment by virtue of patient's impression, the treating neurologist's non-blinded (Yale Global Tic Severity Scale) and a second neurologist's blinded assessment (modified Rush Video Scale). The Yale Global Tic Severity Score improved by 24% on 12.5 mg twice daily and 45% on 12.5 mg thrice daily. Subjective improvement was 50% and 70%, respectively. The modified Rush Video scores improved by 21% and 28.5%, respectively. Post-traumatic tourettism can respond to tetrabenazine. The magnitude of benefit though, may be overestimated with open-label observations, thus there is a need for studies examining objectively the effect of tetrabenazine in tic disorders.


  • Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD

    by Markos Poulopoulos, Etty Cortes, Jean-Paul G. Vonsattel, Stanley Fahn, Cheryl Waters, Lucien J. Cote, Carol Moskowitz, Lawrence S. Honig, Lorraine N. Clark, Karen S. Marder, et al.

    The objective of this study is to describe the neuropathologic findings in three LRRK2 G2019S carriers with Parkinson's disease (PD). We cross-referenced a list of 956 PD individuals that had been previously genotyped in clinical studies at Columbia University, with 282 subjects with a parkinsonian syndrome who came to autopsy in our brain bank since 1991. We found three autopsies of G2019S mutation carriers. Pathological analyses of the samples were blind to the genetic findings. We retrospectively reviewed the clinical records of the three patients. All three had a clinical and pathological diagnosis of PD. Cognitive impairment was a late feature in two out of three patients. Cortical involvement varied significantly: one had diffuse Lewy body (LB) pathology, tau inclusions, and amyloid pathology consistent with advanced Alzheimer's disease; one had diffuse cortical LB; and one had only brainstem predominant LB pathology. Cognitive impairment may be a long-term complication in G2019S mutation carriers. However, the extent of cortical involvement is variable. Larger longitudinal follow-up of LRRK2 G2019S mutation carriers is required to assess for risk factors for cortical involvement and dementia.


  • Open Access

    Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease

    by Markos Poulopoulos

    Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease Markos Poulopoulos, Cheryl WatersDepartment of Neurology, Division of Movement Disorders, Columbia University Medical Center, Neurological Institute of New York, Center of Parkinson’s Disease and Other Movement Disorders, New York, NY, USAIntroduction: Parkinson’s disease (PD) is a common neurodegenerative disease. In the 1960s, it was shown that the degeneration of dopamine producing neurons in the substantia nigra (SN) caused the motor features of PD. Dopamine replacement with levodopa, a dopamine precursor, resulted in remarkable benefit. Yet, the intermittent administration of levodopa is a major cause of motor complications, such as “wearing-off ” of levodopa’s benefit and involuntary movements, known as dyskinesia. Therefore, agents that prolong levodopa’s half-life were employed, such as carbidopa, an aromatic amino acid decarboxylase (AADC) inhibitor, and entacapone, a catechol-O-methyltransferase (COMT) inhibitor. The combination product carbidopa/levodopa/entacapone (CLE) was approved in 2003 for the treatment of PD patients.Aims: To assess the evidence for the place of CLE in the treatment of PD.Evidence review: CLE has a good efficacy, safety and tolerability profile, similar to that of entacapone taken separately with carbidopa/levodopa (CL). Compared to CL alone, it prolongs levodopa’s benefit, and improves the quality of life but not the motor performance in PD patients with nondebilitating “wearing-off ” or dyskinesia. However, it increases the dyskinesia rate in early PD patients, and has adverse events in advanced patients with significant motor complications. There is insufficient evidence regarding cost-effectiveness.Place in therapy: CLE is an attractive alternative for patients with nondisabling “wearing-off ” or dyskinesia taking CL with or without entacapone. It cannot be recommended for early PD patients, as it can induce more dyskinesia than CL alone, or in any patients who seem to have more adverse events.Keywords: Parkinson’s disease, levodopa, entacapone, carbidopa, treatment


  • Neurological complications with acute sphenoid sinusitis a surgical emergency?

    by Markos Poulopoulos, Pasquale F. Finelli

    Isolated acute sphenoid sinusitis is an uncommon sinus infection, frequently misdiagnosed and not usually considered in the differential diagnosis of acute severe headache, with the potential of serious neurologic complications. To describe two patients with acute sphenoid sinusitis who presented with acute onset of severe headache and consider the role of surgical management. Case report Tertiary care hospital Patient 1 developed right cavernous sinus thrombosis and permanent visual loss in one eye, requiring sphenoidotomy following failure of medical treatment. Patient 2 experienced failure of the medical treatment. However, sphenoidotomy abated all his symptoms without any neurologic sequelae. It is important to be aware of acute sphenoid sinusitis in the setting of new onset severe headache, when imaging studies are unrevealing for intracranial pathology. Considering the serious consequences of failed medical treatment vis-à-vis the safety and efficacy of sphenoidotomy we propose surgical intervention at the time of diagnosis.